For research use only. Not for therapeutic Use.
Tulrampator (S-47445) is an orally active selective AMPA receptor modulator. Tulrampator possesses procognitive, enhancing synaptic plasticity, anti-depressant-anxiolytic-like, procognitive and potential neuroprotective properties. Tulrampator can be used for research of alzheimer’s disease and in major depressive disorder[1][2][3].
Tulrampator (0.1 μM, 2 days) markedly enhances the amplitude of the glutamate-evoked current and prolongs the response in HEK-293 cells[1].
Tulrampator (0.1-10 μM, 24 h) shows absence of toxicity on rat primary cortical cells[1].
Tulrampator (0.3-10 mg/kg, Oral gavage, once a day for 4-5 weeks) has anxiolytic-like and antidepressant-like effects in the CORT Mice Model[2].
Tulrampator (1-10 mg/kg, Intraperitoneal injection, once a day for 4 weeks) reverts olfactory bulbectomy (OB)-induced hyperactivity and anxiety in bilateral olfactory bulbectomy mice model[3].
| Catalog Number | I009679 |
| CAS Number | 1038984-31-4 |
| Synonyms | 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7H-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione |
| Molecular Formula | C20H17FN4O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H17FN4O3/c21-13-3-1-2-12(8-13)6-7-25-20(27)15-10-18-16(9-17(15)22-23-25)19(26)24(11-28-18)14-4-5-14/h1-3,8-10,14H,4-7,11H2 |
| InChIKey | JHCFQXNWYDLBOG-UHFFFAOYSA-N |
| SMILES | C1CC1N2COC3=C(C2=O)C=C4C(=C3)C(=O)N(N=N4)CCC5=CC(=CC=C5)F |
| Reference | [1]. Bretin S, et al. Pharmacological characterisation of S 47445, a novel positive allosteric modulator of AMPA receptors [J]. PLoS One, 2017, 12(9): e0184429. [2]. Mendez-David I, et al. S 47445 produces antidepressant-and anxiolytic-like effects through neurogenesis dependent and independent mechanisms [J]. Frontiers in pharmacology, 2017, 8: 462. [3]. Pilar-Cuellar F, et al. S 47445 counteracts the behavioral manifestations and hippocampal neuroplasticity changes in bulbectomized mice [J]. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 93: 205-213. [4]. Wilkinson ST, et al. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. Drug Discov Today. 2018 Nov 14. pii: S1359-6446(18)30376-3. |
